https://www.selleckchem.com/products/plx51107.html
e of non-significantimprovements between the groupsfor most self-management domains (e.g. social integration and support β coefficient 0.34; 95% CI - 0.14 to 0.83) and several quality-of-life domains in favour of the intervention group. These findings support the need for further randomised effectiveness trials of the iVERVE program to be tested in people with new stroke. ANZCTR, ACTRN12618001519246 . Registered on 11 September 2018-retrospectively registered. ANZCTR, ACTRN12618001519246 . Registered on 11 September 2018-retrospectivel